

Medical Policies update

Summary of change: On February 2, 2017, the Medical Policy and Technology Assessment Committee approved the following *Medical Policies* applicable to Amerigroup District of Columbia, Inc. These policies were developed or revised to support clinical coding edits. Several policies were revised to provide clarification only and are not included in the below listing.

The *Medical Policies* were made publicly available on the Amerigroup provider website on the following effective date listed. Visit <u>https://medicalpolicies.amerigroup.com</u> to search for specific policies.

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

| Effective date | Medical policy # | Medical policy title | New or revised |
|----------------|------------------|--|-------------------|
| 3/29/2017 | LAB.00034 | Serological antibody testing for helicobacter pylori | New |
| 3/29/2017 | SURG.00146 | Extracorporeal carbon dioxide removal | New |
| 3/29/2017 | SURG.00147 | Synthetic cartilage implant for metatarsophalangeal joint disorders | New |
| 2/16/2017 | DRUG.00068 | Vedolizumab (Entyvio [®]) | Revised |
| 2/16/2017 | SURG.00103 | Intraocular anterior segment aqueous drainage devices (without extraocular | Revised |

reservoir)

Please note: For markets with pharmacy services carved out, the applicable listings below would be informational only.

The information in this update may be an update or change to your provider manual. Find the most current manual at:



Clinical Utilization Management Guidelines update

Summary: On February 2, 2017, the Medical Policy and Technology Assessment Committee approved the following *Clinical Utilization Management (UM) Guidelines* applicable to Amerigroup District of Columbia, Inc. These clinical guidelines were developed or revised to support clinical coding edits. Several guidelines were revised to provide clarification only and are not included in the following listing. This list represents the *Clinical UM Guidelines* adopted by the Medical Operations Committee for the Government Business Division on March 21, 2017.

On February 2, 2017, the clinical guidelines were made publicly available on the Amerigroup *Medical Policies* and *Clinical UM Guidelines* subsidiary website. Visit <u>https://medicalpolicies.amerigroup.com/search</u> to search for specific guidelines.

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

Please note: For markets with pharmacy services carved out, the applicable listings below would be informational only.

| Effective date | Clinical UM | Clinical UM | New or revised |
|----------------|-------------|------------------------|----------------|
| | Guideline # | <i>Guideline</i> title | |
| 3/29/2017 | CG-MED-56 | Non-obstetrical | New |
| | | transvaginal | |
| | | ultrasonography | |
| 2/16/2017 | CG-DME-38 | Continuous | Revised |
| | | interstitial glucose | |
| | | monitoring | |
| 2/16/2017 | CG-DRUG-28 | Alglucosidase alfa | Revised |
| | | (Lumizyme®) | |
| 2/16/2017 | CG-MED-42 | Maternity ultrasound | Revised |
| | | in the outpatient | |
| | | setting | |
| 2/16/2017 | CG-SURG-27 | Sex reassignment | Revised |
| | | surgery | |

The information in this update may be an update or change to your provider manual. Find the most current manual at: